These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32350906)

  • 41. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Conditions of prescription of anti-TNF agents in newly treated patients with inflammatory bowel disease in France (2011-2013).
    Blotière PO; Rudant J; Barré A; Racine A; Weill A; Peyrin-Biroulet L; Carbonnel F; Alla F
    Dig Liver Dis; 2016 Jun; 48(6):620-5. PubMed ID: 27017107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease.
    Karmi N; Bangma A; Spekhorst LM; van Dullemen HM; Visschedijk MC; Dijkstra G; Weersma RK; Voskuil MD; Festen EAM
    PLoS One; 2021; 16(9):e0256860. PubMed ID: 34534227
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.
    Jeuring SFG; Biemans VBC; van den Heuvel TRA; Zeegers MP; Hameeteman WH; Romberg-Camps MJL; Oostenbrug LE; Masclee AAM; Jonkers DMAE; Pierik MJ
    Am J Gastroenterol; 2018 Mar; 113(3):384-395. PubMed ID: 29317770
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry.
    Bokemeyer B; Hardt J; Hüppe D; Prenzler A; Conrad S; Düffelmeyer M; Hartmann P; Hoffstadt M; Klugmann T; Schmidt C; Weismüller J; Mittendorf T; Raspe H
    J Crohns Colitis; 2013 Jun; 7(5):355-68. PubMed ID: 22503168
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Smoking prevalence and its influence on disease course and surgery in Crohn's disease and ulcerative colitis.
    Lunney PC; Kariyawasam VC; Wang RR; Middleton KL; Huang T; Selinger CP; Andrews JM; Katelaris PH; Leong RW
    Aliment Pharmacol Ther; 2015 Jul; 42(1):61-70. PubMed ID: 25968332
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment and biologic maintenance-dosing patterns among pediatric patients with ulcerative colitis or Crohn's disease.
    Hunter T; Komocsar WJ; Colletti RB; Liu C; Benkov KJ; Dotson JL; Steiner SJ; Zhang N; Crandall W;
    Curr Med Res Opin; 2023 Jan; 39(1):63-69. PubMed ID: 36263735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
    Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Savova G; Churchill S; Karlson EW; Kohane I; Liao KP; Murphy SN
    Inflamm Bowel Dis; 2016 Apr; 22(4):880-5. PubMed ID: 26933751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
    Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
    BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Should biologic agents be stopped before surgery for inflammatory bowel disease?
    Zaghiyan K; McGovern D; Fleshner P
    Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):269-72. PubMed ID: 25366845
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn's disease.
    O'Donnell S; Stempak JM; Steinhart AH; Silverberg MS
    J Crohns Colitis; 2015 Oct; 9(10):830-6. PubMed ID: 26116556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes.
    Koliani-Pace JL; Singh S; Luo M; Hirten R; Aniwan S; Kochhar G; Chang S; Lukin D; Gao Y; Bohm M; Swaminath A; Gupta N; Shmidt E; Meserve J; Winters A; Chablaney S; Faleck DM; Yang J; Huang Z; Boland BS; Shashi P; Weiss A; Hudesman D; Varma S; Fischer M; Sultan K; Shen B; Kane S; Loftus EV; Sands BE; Colombel JF; Sandborn WJ; Lasch K; Siegel CA; Dulai PS
    Inflamm Bowel Dis; 2019 Oct; 25(11):1854-1861. PubMed ID: 31050734
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inflammatory bowel disease among Bedouin Arabs in southern Israel: urbanization and increasing prevalence rates.
    Abu Freha N; Schwartz D; Elkrinawi J; Ben Yakov G; Abu Tailakh M; Munteanu D; Abu Ganim A; Fich A
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):230-4. PubMed ID: 25563139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis.
    Szamosi T; Banai J; Lakatos L; Czegledi Z; David G; Zsigmond F; Pandur T; Erdelyi Z; Gemela O; Papp M; Papp J; Lakatos PL
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):872-9. PubMed ID: 19648821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.
    Korzenik J; Larsen MD; Nielsen J; Kjeldsen J; Nørgård BM
    Aliment Pharmacol Ther; 2019 Aug; 50(3):289-294. PubMed ID: 31267570
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
    Gisbert JP; Marín AC; McNicholl AG; Chaparro M
    Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IMPORTANCE OF MEASURING LEVELS OF INFLIXIMAB IN PATIENTS TREATING INFLAMMATORY BOWEL DISEASE IN A BRAZILIAN COHORT.
    Kampa KC; Morsoletto DBG; Loures MR; Pissaia A; Nones RB; Ivantes CAP
    Arq Gastroenterol; 2017 Dec; 54(4):333-337. PubMed ID: 28954041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.